DelMar Pharmaceuticals, Inc. (DMPI)
(Delayed Data from NSDQ)
$0.36 USD
0.00 (0.97%)
Updated May 3, 2019 03:59 PM ET
After-Market: $0.36 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Kintara Therapeutics, Inc. [DMPI]
Reports for Purchase
Showing records 1 - 20 ( 108 total )
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
BUY: Adgero Call Reveals the Light Behind the Strategy
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
BUY: Positive interim data on VAL-083 at AACR
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
BUY: Acquires a Phase 3 Oncology Company (Adgero) for Stock
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
BUY: A Clinical and Financial Path Forward as GCAR Selects VAL-083 for the GBM AGILE Pivotal Study
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
BUY: A Clinical and Financial Path Forward as GCAR Selects VAL-083 for the GBM AGILE Pivotal Study
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
BUY- Reports the Quarter, Trial Progress Continues
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
Halfway There -P2 Adjuvant Trial in Brain Cancer
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
Reports the Quarter with Expense Control - Runway
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
Two Posters at SNO; Interim Data Looks Promising
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
Closes June Fiscal Year on an Optimistic Note
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
Raises Precious Capital- Creating Runway for VAL 083
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
VAL-083; First Patient Treated MD Anderson Center
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
VAL-083; Creating Value in the Adjuvant Setting
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
We are transferring coverage of DelMar and introducing a new price target of $3.0.
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
Terminating coverage due to reallocation of resources.
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
Patient Enrollment Accelerates in Phase 2 Brain Cancer Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kintara Therapeutics, Inc.
Industry: Medical - Drugs
F3Q18 Financial Results Reported; Interim CEO Made Permanent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R